All news from Cardiology

Cardiac Event Detects Patients & Plaques Vulnerable To Subsequent Coronary Events

Results from the Lipid-Rich Plaque (LRP) study demonstrate the correlation between the presence of non-flow-limiting, non-intervened upon, lipid-rich plaques detected by NIRS-IVUS imaging and the development of a major adverse cardiac event (MACE ) from a de novo culprit lesion at both the patient level (vulnerable patients) and segment level (vulnerable plaques) within 24 months post intravascular imaging.

Heart Patients Should Move For Every 20 Minutes To Prolong Life

Heart patients are being advised to move around every 20 minutes in a bid to prolong life following a study presented at the Canadian Cardiovascular Congress (CCC) 2018. CCC 2018 is being held 20 to 23 October in Toronto, Canada.

Visiting experts from the European Society of Cardiology (ESC) will participate in joint scientific sessions with the Canadian Cardiovascular Society (CCS) as part of the ESC Global Activities program.

Heart patients spend most of their waking hours sitting, lying down, and watching television Previous research has shown that being sedentary for long periods could shorten life but taking breaks to move around may counteract the risk, particularly if it means burning more than 770 kcal day This study investigated how many breaks, and for what duration, are needed to expend 770 kcal.

Effects & Costs Of Home-Based Rehabilitation for Heart Failure With Reduced Ejection Fraction

A new study has found that the Rehabilitation Enablement in Chronic Heart Failure (REACH-HF) program, led by the University of Exeter and the Royal Cornwall Hospitals NHS trust, significantly improved quality of life and is deliverable within NHS cost guidelines.

The program was co-designed by clinicians, academics, patients, and caregivers to help increase participation in rehabilitation therapies for heart failure. The five-year study received £ 2million in grant funding from the National Institute for Health Research (NIHR) under its Program Grants for Applied Research program with contributions from a number of clinical and academic partners from across the UK including Exeter, Gwent, Birmingham, York, and Dundee.

The study was published in the European Journal of Preventive Cardiology.

Generation Of Heart Risk Factors May Decrease Brain Function

It's been 70 years since a small, middle-class community 23 miles west of Boston became the linchpin in helping to solve the mysteries of heart disease.  Cholesterol Blood pressure. Obesity It's common knowledge today that these all lead to heart trouble.

But in the 1940s, with one in two deaths caused by cardiovascular disease and even after President Franklin Roosevelt died from the effects of heart failure and a massive stroke, the information would have been considered revolutionary.

Blood Pressure Treatment Guideline Recommendations and Cardiovascular Risk

Researchers assessed the risk for CVD events among adults and recommended antihypertensive medication initiation or intensification based on 2017 ACC / AHA blood pressure guideline. Participants (aged ≥45 years) were part of the REGARDS (REasons for Geographic and Racial Differences in Stroke) study cohort, and their systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured twice at baseline (2003 to 2007) and averaged. CVD events (stroke, coronary heart disease, and heart failure) were tracked through 2014.

Machine Learning Model Predicts The Risk Of Death In Heart Disease Patients

A new study examines that artificial intelligence (AI) is better at predicting the risk of death in patients with heart disease than models designed by medical experts.  The study was published in PLOS One, adds to the growing evidence that AI could revolutionize healthcare in the UK and beyond. So far, the emphasis has been on the potential of AI to help diagnose and treat various diseases, but these new findings suggest it could also help predict the likelihood of patients dying too.

Ventricular Tachycardia Reduced In Patients With Defibrillators

A clinical trial of more than 1,000 patients with implantable cardioverter defibrillators (ICDs) found that the drug ranolazine (commonly used to treat chest pain; brand name Ranexa) was safe but didn't significantly decrease the likelihood of the first occurrence of ventricular tachycardia, ventricular fibrillation or death in this high-risk population. The study was published recently in JACC, the Journal of the American College of Cardiology.